GLMD
Closed
Galmed Pharmaceuticals Ltd
1.78
-0.06 (-3.26%)
Last Update: 01 Jul 2025 23:11:00
Yesterday: 1.84
Day's Range: 1.7401 - 1.85
Send
sign up or login to leave a comment!
When Written:
0.37
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company that focuses on developing therapies for liver diseases and other inflammatory disorders. The company's lead candidate, Aramchol, is a novel fatty acid bile acid conjugate that is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a chronic liver disease that affects millions of people worldwide.
Galmed Pharmaceuticals was founded in 2000 and is headquartered in Tel Aviv, Israel. The company is listed on the NASDAQ stock exchange under the ticker symbol "GLMD." In addition to Aramchol, the company has a pipeline of other drug candidates in various stages of development, including a topical treatment for psoriasis and a treatment for primary sclerosing cholangitis (PSC), a rare liver disease.
Galmed Pharmaceuticals has partnerships and collaborations with several academic institutions and pharmaceutical companies, including the University of Liverpool, the University of Miami, and MyBiotics Pharma Ltd. The company has also received funding from various sources, including the Israeli Innovation Authority and the European Union's Horizon 2020 research and innovation program.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Galmed Pharmaceuticals was founded in 2000 and is headquartered in Tel Aviv, Israel. The company is listed on the NASDAQ stock exchange under the ticker symbol "GLMD." In addition to Aramchol, the company has a pipeline of other drug candidates in various stages of development, including a topical treatment for psoriasis and a treatment for primary sclerosing cholangitis (PSC), a rare liver disease.
Galmed Pharmaceuticals has partnerships and collaborations with several academic institutions and pharmaceutical companies, including the University of Liverpool, the University of Miami, and MyBiotics Pharma Ltd. The company has also received funding from various sources, including the Israeli Innovation Authority and the European Union's Horizon 2020 research and innovation program.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








